Phase 2 Trial Shows Dalantercept Has Limited Effectiveness in Ovarian Cancer Patients

Phase 2 Trial Shows Dalantercept Has Limited Effectiveness in Ovarian Cancer Patients
A Phase 2 clinical trial determined that treatment with dalantercept, an inhibitor of blood vessel maturation, is safe but has limited effectiveness in ovarian cancer patients, none of whom responded to the investigational therapy. The clinical development of the investigational therapy has been discontinued. Trial findings were published in the study, "Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study," in the journal Gynecologic Oncology. Angiogenesis, which refers to the formation of new blood vessels, is essential during normal growth and development. It also plays a critical role in the growth and spread of cancer cells, since it ensures a supply of blood to the newly spread cancer cells. As a result, targeting angiogenesis is one strategy that can be used to combat cancer. There are two main steps involved in angiogenesis: activation — where blood vessel-forming cells divide — and maturation. The current rationale is that blocking the maturation phase may be a broader approach for cancer treatment. The activin receptor-like kinase 1 (ALK1) protein is involved in the maturation phase and is therefore a potential therapy target. Dalantercept, by Acceleron Pharma, is a synthetic protein that blocks ALK1 activity and had proven promising in a
Subscribe or to access all post and page content.